The Time Is Ripe for a Randomized Trial of Metformin in Clinically Localized Prostate Cancer
Bibliographic record
Abstract
In a population study making excellent use of Ontario’s universal health plan electronic data, Margel et al 1 showed increasing duration of metformin use among diabetic men after a diagnosis of prostate cancer was associated with decreased prostate cancer–specific and all-cause mortality. Prostate cancer–specific mortality decreased by 24% for each additional 6 months of metformin use after diagnosis; use of other antidiabetic medications did not significantly decrease prostate cancer–specific mortality. The authors were thorough in their investigation, performing many sensitivity analyses to attempt to rule out possible biases. As the distribution of clinical characteristics specific to metformin users and nonusers was not provided, it is difficult to assess the possibility of residual confounding; however, the authors appropriately adjusted for many covariates. Also, the specificity of the results for metformin lends further support for causal relation. Interestingly, although postdiagnostic use of metformin was highly significant, the association of cumulative metformin use before prostate cancer diagnosis with prostate cancer death was null. As prostate cancer date of diagnosis is a rather arbitrary point in the progression of the disease, this discrepancy between the impact of pre- and postdiagnostic use is perplexing and warrants further study. Despite these concerns, the authors provide a convincing case for a causal interpretation and for initiating a randomized trial of metformin among men with localized prostate cancer at diagnosis. The potential benefits of metformin could exceed those of existing drug therapies, particularly given its safety profile. Margel et al 1 wisely chose to focus their analysis on prostate cancer mortality. Of course, this is clinically the most important out
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.024 | 0.061 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.003 | 0.006 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.001 | 0.001 |
| Scholarly communication | 0.003 | 0.002 |
| Open science | 0.002 | 0.001 |
| Research integrity | 0.009 | 0.009 |
| Insufficient payload (model declined to judge) | 0.008 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".